Medical/Pharmaceuticals
Dimora Medical Recognized as Key Driver in Winner Medical's Amazon Award
NEW YORK, Dec. 9, 2025 /PRNewswire/ -- Winner Medical, the parent company of Dimora Medical, has been honored with the Paid Service Operation Excellence Award at the 2025 Amazon Global Selling Seller Conference, which focuses on excellence, innovation and global market. As one of Winner Medical's...
2025-12-09 18:35
652
Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights includ...
2025-12-09 18:00
745
Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen (oxaliplatin + tegafur/gimeracil/oteracil) as n...
2025-12-09 15:50
692
GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy
YONGIN, South Korea, Dec. 9, 2025 /PRNewswire/ -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its study analyzing cell-free DNA (cfDNA) fragmentation patterns in 1,154 healthy individuals has been published in Clinical Chemistry (Impact Factor 6.3, 2025). The ...
2025-12-09 14:54
722
Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
HONG KONG, Dec. 8, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by ProfessorShun Lu from Shanghai Chest Hospital. The ...
2025-12-09 10:02
883
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
2025-12-09 08:00
789
Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration & beyond
SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a$10 million Seed financing round. The round was invested by Qiming Venture Partn...
2025-12-08 23:00
1023
ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY 2026
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ALR Technologies SG Ltd ("ALRT" or the " Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve") showing accuracy results comparative to the leading v...
2025-12-08 22:14
1842
Zymedi Announces "rapaprutug" as the International Nonproprietary Name (INN) for ZMA001
INCHEON, South Korea, Dec. 8, 2025 /PRNewswire/ -- Zymedi (CEO Sunghoon Kim) announced that the World Health Organization (WHO) has assignedrapaprutug as the International Nonproprietary Name (INN) for the company's first-in-class antibody therapy ZMA001, being developed as a treatment for pulmon...
2025-12-08 22:00
618
Lunit Submits 510(k) Application for Image-Based Breast Cancer Risk Prediction Model
Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that ...
2025-12-08 22:00
669
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first sh...
2025-12-08 14:36
651
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...
2025-12-08 10:08
960
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
NANJING, China, Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation o...
2025-12-08 10:00
801
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceuticalcompany focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignanc...
2025-12-08 09:57
707
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-12-08 09:02
977
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/r...
2025-12-08 08:15
843
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtage...
2025-12-07 17:21
1350
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released byChina's National Healthcare Securi...
2025-12-07 14:18
1316
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-12-07 11:40
1637
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in viv...
2025-12-06 22:45
1755
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4847
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
2025-12-05 21:45
4093
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3950
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3868
